Patents by Inventor Ryan HEESBEEN
Ryan HEESBEEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957763Abstract: The invention relates to a novel linker for use in bioconjugates such as antibody-drug-conjugates. The linker according to the invention is represented by formula: wherein: BM is a branching moiety; E is a capping group; SG is a sulfamide group; b, c, d, e, g, i, k, l are independently 0 or 1; f is an integer in the range of 1 to 10; Sp1, Sp2, Sp3, Sp4, Sp5 and Sp6 are a spacer moieties; Z1 and Z2 are connecting groups. The linker according to the invention is useful in the preparation of linker-conjugates and bioconjugates, and can be used for (a) improving conjugation efficiency in the preparation of the bioconjugate, (b) reducing aggregation during the preparation of the bioconjugate and/or of the bioconjugate, (c) increasing stability of the bioconjugate, and/or (d) increasing therapeutic index of the bioconjugate.Type: GrantFiled: December 28, 2020Date of Patent: April 16, 2024Assignee: SYNAFFIX B.V.Inventors: Sander Sebastiaan Van Berkel, Ryan Heesbeen, Jorge Merijn Mathieu Verkade, Maria Antonia Wijdeven, Floris Louis Van Delft
-
Publication number: 20230127659Abstract: The present invention concerns novel and improved antibody-conjugates for targeting HER2. The inventors found that when antibody-conjugates were prepared using a specific mode of conjugation, they exhibit an improved therapeutic index.Type: ApplicationFiled: May 20, 2022Publication date: April 27, 2023Applicant: SYNAFFIX B.V.Inventors: Sander Sebastiaan VAN BERKEL, Jorge Merijn Mathieu VERKADE, Maria Antonia WIJDEVEN, Ryan HEESBEEN, Petrus Josephus Jacobus Maria VAN DE SANDE, Remon VAN GEEL, Brian Maria Gerardus JANSSEN, Inge Catharina Josephina HURKMANS, Floris Louis VAN DELFT
-
Patent number: 11590239Abstract: The present invention concerns novel and improved antibody-conjugates for targeting CD30. The inventors found that when antibody-conjugates were prepared using a specific mode of conjugation, they exhibit an improved therapeutic index.Type: GrantFiled: February 8, 2017Date of Patent: February 28, 2023Assignee: SYNAFFIX B.V.Inventors: Sander Sebastiaan Van Berkel, Jorge Merijn Mathieu Verkade, Maria Antonia Wijdeven, Ryan Heesbeen, Petrus Josephus Jacobus Maria Van De Sande, Remon Gvan Eel, Brian Maria Gerardus Janssen, Inge Catharina Josephina Hurkmans, Floris Louis Van Delft
-
Patent number: 11338043Abstract: The present invention concerns novel and improved antibody-conjugates for targeting HER2. The inventors found N that when antibody-conjugates were prepared using a specific mode of conjugation, they exhibit an improved therapeutic index.Type: GrantFiled: February 8, 2017Date of Patent: May 24, 2022Assignee: SYNAFFIX B.V.Inventors: Sander Sebastiaan Van Berkel, Jorge Merijn Mathieu Verkade, Maria Antonia Wijdeven, Ryan Heesbeen, Petrus Josephus Jacobus Maria Van De Sande, Remon Van Geel, Brian Maria Gerardus Janssen, Inge Catharina Josephina Hurkmans, Floris Louis Van Delft
-
Publication number: 20210353766Abstract: The invention relates to a novel linker for use in bioconjugates such as antibody-drug-conjugates. The linker according to the invention is represented by formula: wherein: BM is a branching moiety; E is a capping group; SG is a sulfamide group; b, c, d, e, g, i, k, l are independently 0 or 1; f is an integer in the range of 1 to 10; Sp1, Sp2, Sp3, Sp4, Sp5 and Sp6 are a spacer moieties; Z1 and Z2 are connecting groups. The linker according to the invention is useful in the preparation of linker-conjugates and bioconjugates, and can be used for (a) improving conjugation efficiency in the preparation of the bioconjugate, (b) reducing aggregation during the preparation of the bioconjugate and/or of the bioconjugate, (c) increasing stability of the bioconjugate, and/or (d) increasing therapeutic index of the bioconjugate.Type: ApplicationFiled: December 28, 2020Publication date: November 18, 2021Applicant: SYNAFFIX B.V.Inventors: Sander Sebastiaan VAN BERKEL, Ryan HEESBEEN, Jorge Merijn Mathieu VERKADE, Maria Antonia WIJDEVEN, Floris Louis VAN DELFT
-
Patent number: 10874746Abstract: The invention relates to a novel linker for use in bioconjugates such as antibody-drug-conjugates. The linker according to the invention is represented by formula: (I) wherein: —BM is a branching moiety; —E is a capping group; —SG is a sulfamide group; —b, c, d, e, g, i, k, l are independently 0 or 1; —f is an integer in the range of 1 to 10; —Sp1, Sp2, Sp3, Sp4, Sp5 and Sp6 are a spacer moieties; —Z1 and Z2 are connecting groups. The linker according to the invention is useful in the preparation of linker-conjugates and bioconjugates, and can be used for (a) improving conjugation efficiency in the preparation of the bioconjugate, (b) reducing aggregation during the preparation of the bioconjugate and/or of the bioconjugate, (c) increasing stability of the bioconjugate, and/or (d) increasing therapeutic index of the bioconjugate.Type: GrantFiled: February 8, 2017Date of Patent: December 29, 2020Assignee: SYNAFFIX B.V.Inventors: Sander Sebastiaan Van Berkel, Ryan Heesbeen, Jorge Merijn Mathieu Verkade, Maria Antonia Wijdeven, Floris Louis Van Delft
-
Publication number: 20190262466Abstract: The present invention concerns novel and improved antibody-conjugates for targeting HER2. The inventors found N that when antibody-conjugates were prepared using a specific mode of conjugation, they exhibit an improved therapeutic index.Type: ApplicationFiled: February 8, 2017Publication date: August 29, 2019Applicant: SYNAFFIX B.V.Inventors: Sander Sebastiaan VAN BERKEL, Jorge Merijn Mathieu VERKADE, Maria Antonia WIJDEVEN, Ryan HEESBEEN, Petrus Josephus Jacobus Maria VAN DE SANDE, Remon VAN GEEL, Brian Maria Gerardus JANSSEN, Inge Catharina Josephina HURKMANS, Floris Louis VAN DELFT
-
Publication number: 20190262468Abstract: The present invention concerns novel and improved antibody-conjugates for targeting CD30. The inventors found that when antibody-conjugates were prepared using a specific mode of conjugation, they exhibit an improved therapeutic index.Type: ApplicationFiled: February 8, 2017Publication date: August 29, 2019Inventors: Sander Sebastiaan VAN BERKEL, Jorge Merijn Mathieu VERKADE, Maria Antonia WIJDEVEN, Ryan HEESBEEN, Petrus Josephus Jacobus Maria VAN DE SANDE, Remon GVAN EEL, Brian Maria Gerardus JANSSEN, Inge Catharina Josephina HURKMANS, Floris Louis VAN DELFT
-
Publication number: 20190225706Abstract: The invention relates to a glycoprotein comprising an optionally fucosylated glycan according to formula (105) or (106), wherein Su(A)x is a modified sugar moiety comprising one or more functional groups A. Functional group A is independently selected from the group consisting of a thiol group, a halogen, a sulfonyloxy group, a halogenated acetamido group, a mercaptoacetamido group and a sulfonated hydroxyacetamido group. The invention also relates to a glycoprotein-conjugate wherein a glycoprotein according to the invention is conjugated to a molecule of interest. Said molecule of interest may for example be an active substance. The invention further relates to a process for the preparation of a modified glycoprotein, and to a method for the preparation of a glycoprotein-conjugate. The invention particularly relates to modified antibodies, antibody-conjugates, antibody-drug conjugates and methods for the preparation thereof.Type: ApplicationFiled: August 28, 2018Publication date: July 25, 2019Applicant: SynAffix B.V.Inventors: Floris Louis VAN DELFT, Remon VAN GEEL, Maria Antonia WIJDEVEN, Jorge Merijn Mathieu VERKADE, Ryan HEESBEEN
-
Patent number: 10266502Abstract: The present invention relates to a cycloaddition process comprising the step of reacting a halogenated aliphatic 1,3-dipole compound with a (hetero)cycloalkyne according to Formula (1): Preferably, the (hetero)cycloalkyne according to Formula (1) is a (hetero)cyclooctyne. The invention also relates to the cycloaddition products obtainable by the process according to the invention. The invention further relates to halogenated aliphatic 1,3-dipole compounds, in particular to halogenated aliphatic 1,3-dipole compounds comprising N-acetylgalactosamine-UDP (GalNAc-UDP), and to halogenated 1,3-dipole compounds comprising (peracylated) N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), N-acetylmannosamine (ManNAc) and N-acetyl neuraminic acid (NeuNAc).Type: GrantFiled: January 26, 2015Date of Patent: April 23, 2019Assignee: SYNAFFIX B.V.Inventors: Floris Louis Van Delft, Remon Van Geel, Maria Antonia Wijdeven, Ryan Heesbeen
-
Publication number: 20190038765Abstract: The invention relates to a novel linker for use in bioconjugates such as antibody-drug-conjugates. The linker according to the invention is represented by formula: (I) wherein: —BM is a branching moiety; —E is a capping group; —SG is a sulfamide group; —b, c, d, e, g, i, k, l are independently 0 or 1; —f is an integer in the range of 1 to 10; —Sp1, Sp2, Sp3, Sp4, Sp5 and Sp6 are a spacer moieties; —Z and Z2 are connecting groups. The linker according to the invention is useful in the preparation of linker-conjugates and bioconjugates, and can be used for (a) improving conjugation efficiency in the preparation of the bioconjugate, (b) reducing aggregation during the preparation of the bioconjugate and/or of the bioconjugate, (c) increasing stability of the bioconjugate, and/or (d) increasing therapeutic index of the bioconjugate.Type: ApplicationFiled: February 8, 2017Publication date: February 7, 2019Applicant: SYNAFFIX B.V.Inventors: Sander Sebastiaan VAN BERKEL, Ryan HEESBEEN, Jorge Merijn Mathieu VERKADE, Maria Antonia WIJDEVEN, Floris Louis VAN DELFT
-
Patent number: 10072096Abstract: The invention relates to a glycoprotein comprising an optionally fucosylated glycan according to formula (105) or (106), wherein Su(A)x is a modified sugar moiety comprising one or more functional groups A. Functional group A is independently selected from the group consisting of a thiol group, a halogen, a sulfonyloxy group, a halogenated acetamido group, a mercaptoacetamido group and a sulfonated hydroxyacetamido group. The invention also relates to a glycoprotein-conjugate wherein a glycoprotein according to the invention is conjugated to a molecule of interest. Said molecule of interest may for example be an active substance. The invention further relates to a process for the preparation of a modified glycoprotein, and to a method for the preparation of a glycoprotein-conjugate. The invention particularly relates to modified antibodies, antibody-conjugates, antibody-drug conjugates and methods for the preparation thereof.Type: GrantFiled: October 14, 2014Date of Patent: September 11, 2018Assignee: SYNAFFIX B.V.Inventors: Floris Louis Van Delft, Remon Van Geel, Maria Antonia Wijdeven, Jorge Merijn Mathieu Verkade, Ryan Heesbeen
-
Publication number: 20170009266Abstract: The present invention relates to a process for attaching an N-acetylgalactosamine-(hetero)arylmoiety to an N-acetylglucosaminemoiety, the process comprising the step of contacting the N-acetylgalactosamine-(hetero)arylmoiety with the N-acetylglucosaminemoiety in the presence of a mutant galactosyltransferase, wherein the N-acetylglucosaminemoiety is according to Formula (1) the N-acetylgalactosamine-(hetero)arylmoiety is according to Formula (2): In a particularly preferred embodiment of the process according to the invention, the N-acetylgalactosamine-(hetero)arylmoiety comprises a 1,3-dipole functional group, and the N-acetylglucosaminemoiety is a terminal GlcNAc moiety of a glycoprotein glycan. The invention further relates to a product obtainable by the process according to the invention, in particular to glycoproteins. Also, the invention relates to several compounds comprising an N-acetylgalactosamine-(hetero)arylmoiety.Type: ApplicationFiled: January 26, 2015Publication date: January 12, 2017Applicant: SynAffix B.V.Inventors: Floris Louis VAN DELFT, Remon VAN GEEL, Maria Antonia WIJDEVEN, Ryan HEESBEEN
-
Publication number: 20170008858Abstract: The present invention relates to a cycloaddition process comprising the step of reacting a halogenated aliphatic 1,3-dipole compound with a (hetero)cycloalkyne according to Formula (1): Preferably, the (hetero)cycloalkyne according to Formula (1) is a (hetero)cyclooctyne. The invention also relates to the cycloaddition products obtainable by the process according to the invention. The invention further relates to halogenated aliphatic 1,3-dipole compounds, in particular to halogenated aliphatic 1,3-dipole compounds comprising N-acetylgalactosamine-UDP (GalNAc-UDP), and to halogenated 1,3-dipole compounds comprising (peracylated) N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), N-acetylmannosamine (ManNAc) and N-acetyl neuraminic acid (NeuNAc).Type: ApplicationFiled: January 26, 2015Publication date: January 12, 2017Applicant: SynAffix B.V.Inventors: Floris Louis VAN DELFT, Remon VAN GEEL, Maria Antonia WIJDEVEN, Ryan HEESBEEN
-
Publication number: 20160280797Abstract: The invention relates to a glycoprotein comprising an optionally fucosylated glycan according to formula (105) or (106), wherein Su(A)x is a modified sugar moiety comprising one or more functional groups A. Functional group A is independently selected from the group consisting of a thiol group, a halogen, a sulfonyloxy group, a halogenated acetamido group, a mercaptoacetamido group and a sulfonated hydroxyacetamido group. The invention also relates to a glycoprotein-conjugate wherein a glycoprotein according to the invention is conjugated to a molecule of interest. Said molecule of interest may for example be an active substance. The invention further relates to a process for the preparation of a modified glycoprotein, and to a method for the preparation of a glycoprotein-conjugate. The invention particularly relates to modified antibodies, antibody-conjugates, antibody-drug conjugates and methods for the preparation thereof.Type: ApplicationFiled: October 14, 2014Publication date: September 29, 2016Applicant: SynAffix B.V.Inventors: Floris Louis VAN DELFT, Remon VAN GEEL, Maria Antonia WIJDEVEN, Jorge Merijn Mathieu VERKADE, Ryan HEESBEEN
-
Publication number: 20160235861Abstract: The invention relates to glycoengineered antibodies and antibody-conjugates. In particular, the invention relates to an antibody conjugate, prepared from IgG antibody comprising at least two N-linked glycosylation sites on the combination of a single heavy chain and single light chain. The invention further relates to methods for the preparation of the antibody-conjugates according to the invention. In particular, the invention relates to an antibody-drug conjugate that is conjugated to different toxins, and the a process for the preparation thereof.Type: ApplicationFiled: October 14, 2014Publication date: August 18, 2016Applicant: SynAffix. B.V.Inventors: Floris Louis VAN DELFT, Remon VAN GEEL, Maria Antonia WIJDEVEN, Jorge Merijn Mathieu VERKADE, Ryan HEESBEEN